List of Excipients in Branded Drug YONDELIS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Janssen Products LP	YONDELIS	trabectedin	59676-610	MONOBASIC POTASSIUM PHOSPHATE	1969-12-31
Janssen Products LP	YONDELIS	trabectedin	59676-610	PHOSPHORIC ACID	1969-12-31
Janssen Products LP	YONDELIS	trabectedin	59676-610	POTASSIUM HYDROXIDE	1969-12-31
Janssen Products LP	YONDELIS	trabectedin	59676-610	SUCROSE	1969-12-31

YONDELIS Excipient Strategy and Commercial Opportunities for Trabectedin Injection

Last updated: September 30, 2026

YONDELIS is an intravenous trabectedin product for advanced soft-tissue sarcoma and relapsed platinum-sensitive ovarian cancer. Its excipient profile is relatively simple: a lyophilized powder containing sucrose, phosphate buffer components, phosphoric acid, and sodium hydroxide, followed by reconstitution and dilution before infusion. The main commercial opportunities are not conventional oral excipient substitution. They are concentrated in sterile manufacturing, lyophilization, container-closure systems, infusion compatibility, ready-to-use presentations, and generic or alternative injectable development.

What excipients are used in YONDELIS?

YONDELIS is supplied as a 1-mg single-dose vial containing trabectedin as a sterile lyophilized powder. The US product is reconstituted with Sterile Water for Injection and then diluted in either 0.9% Sodium Chloride Injection or 5% Dextrose Injection before intravenous administration.[1]

Product element	YONDELIS approach
Active ingredient	Trabectedin
Dosage form	Sterile lyophilized powder for injection
Strength	1 mg per vial
Primary route	Intravenous infusion
Core excipients	Sucrose, potassium phosphate monobasic, phosphoric acid, sodium hydroxide
Reconstitution diluent	Sterile Water for Injection
Final dilution	0.9% sodium chloride or 5% dextrose
Administration	Intravenous infusion over 24 hours
Container	Single-dose glass vial
Key handling issue	Cytotoxic drug preparation and controlled infusion

The European product information identifies sucrose, potassium dihydrogen phosphate, phosphoric acid, and sodium hydroxide among the excipients.[2] Potassium phosphate monobasic and potassium dihydrogen phosphate refer to the same phosphate salt nomenclature.

Sucrose has a primary role as a bulking and stabilizing agent in the lyophilized cake. Phosphate provides buffering capacity, while phosphoric acid and sodium hydroxide support pH adjustment during formulation development. The excipient system is designed for a parenteral product that must maintain chemical stability during freeze-drying, storage, reconstitution, and prolonged infusion.

How does the YONDELIS formulation work?

The formulation strategy is based on a low-excipient, freeze-dried presentation rather than a liquid concentrate. This approach reduces the amount of water present during long-term storage and can improve stability for a complex cytotoxic small molecule.

Why is lyophilization used?

Lyophilization can reduce hydrolytic degradation and permit storage of the drug as a dry cake. For trabectedin, the process must control:

• Freezing behavior and ice-crystal formation.
• Collapse temperature and cake structure.
• Residual moisture.
• Reconstitution time.
• Drug adsorption to glass, stoppers, tubing, and infusion bags.
• Degradation during the 24-hour infusion period.

Sucrose is commercially important because it can provide both cake structure and stabilization. Its concentration must be balanced against cake appearance, reconstitution performance, osmolality, and residual moisture.

What are the critical quality attributes?

A trabectedin injectable must control more than assay and sterility. Commercially relevant quality attributes include:

Quality attribute	Commercial relevance
Potency and related substances	Limits degradation and supports release testing
Sterility and endotoxin	Required for intravenous oncology use
Visible and subvisible particles	Important for a prolonged infusion
Residual moisture	Affects stability and cake integrity
Reconstitution time	Influences pharmacy workflow
pH after reconstitution	Affects stability and compatibility
Particulate shedding	Relevant to vial, stopper, and transfer devices
Container-closure integrity	Required for a cytotoxic sterile product
Infusion-bag compatibility	Supports hospital administration
Stability after dilution	Determines pharmacy beyond-use handling

What excipient opportunities exist for YONDELIS generics?

The strongest opportunity is a generic or alternative trabectedin injection that matches the reference product's performance without copying its formulation unnecessarily. A prospective applicant could use the same broad excipient classes or develop a distinct stabilizer and buffer system, subject to regulatory comparability and product-specific requirements.

Opportunity 1: Alternative lyophilized formulations

Potential development routes include:

• Sucrose-based formulations with optimized phosphate concentration.
• Trehalose or other nonreducing sugars as alternative stabilizers.
• Histidine or citrate buffering, if compatible with trabectedin stability and intravenous administration.
• Reduced-phosphate systems to lower precipitation or compatibility risk.
• Improved cake structures that reduce reconstitution time.
• Lower residual-moisture formulations for longer shelf life.

A formulation change would create development work around degradation pathways, pH drift, reconstitution, extractables and leachables, and infusion compatibility. A substitute excipient is commercially attractive only if it produces a measurable benefit, such as improved stability, simpler manufacture, or a lower cost of goods.

Opportunity 2: Ready-to-use or pharmacy-friendly presentations

YONDELIS requires aseptic reconstitution and dilution before a 24-hour infusion. A ready-to-use liquid bag, dual-chamber container, or pharmacy-compounded presentation could reduce preparation steps.

The regulatory burden would be materially higher than for a conventional lyophilized generic. A liquid presentation would require evidence covering:

• Long-term chemical stability.
• Photostability.
• Adsorption to the primary container.
• Compatibility with infusion tubing and pumps.
• Particulate control.
• Preservative strategy, if any.
• Microbiological control after opening or activation.
• Stability during the full administration period.

A ready-to-use product could command a premium if it reduces hazardous-drug handling, preparation time, and medication-error risk. The commercial case is strongest for hospitals with high oncology pharmacy volumes.

Opportunity 3: Improved container-closure systems

The vial, stopper, seal, and transfer process are part of the formulation strategy. Potential product differentiation includes:

• Low-extractables elastomeric stoppers.
• Coated stoppers that reduce adsorption.
• Integrated transfer devices.
• Closed-system drug-transfer compatibility.
• Single-use reconstitution systems.
• Improved vial labeling and cytotoxic handling controls.

These improvements may not create independent pharmaceutical patent protection, but they can support device, packaging, or process claims and create procurement advantages.

Opportunity 4: Infusion compatibility packages

The label permits dilution in 0.9% sodium chloride or 5% dextrose.[1] A developer could generate a broader compatibility package covering:

• Common infusion bags.
• Polyolefin and PVC tubing.
• Inline filters.
• Elastomeric pumps.
• Light exposure.
• Temperature excursions.
• Administration beyond the labeled period.
• Closed-system transfer devices.

Compatibility data can influence hospital formulary adoption even when the active ingredient is identical. The value is operational rather than therapeutic.

What formulation patents protect YONDELIS?

The relevant IP position has several layers:

1. Trabectedin compound patents.
2. Synthetic and manufacturing patents.
3. Pharmaceutical composition and formulation patents.
4. Methods of use in sarcoma and ovarian cancer.
5. Process, packaging, and device-related rights.

YONDELIS was developed by PharmaMar and approved in the United States under NDA 022225.[1] The original active-ingredient and development-related patent portfolio is distinct from any later formulation or manufacturing patents.

Are formulation patents the main barrier?

For a generic injectable, formulation patents may be less important than manufacturing and regulatory execution. A noninfringing applicant can potentially develop an alternative excipient system, but it still must demonstrate:

• Pharmaceutical equivalence.
• Bioequivalence or an accepted alternative to conventional bioequivalence.
• Sterility assurance.
• Comparable product quality.
• Stability through administration.
• Safe handling of a cytotoxic drug.

The practical barrier is often the ability to reproduce a stable sterile lyophilized product at commercial scale. A formulation that works in laboratory vials may fail during lyophilizer scale-up because of cake collapse, fill-volume variation, vial breakage, or batch-to-batch moisture differences.

When does YONDELIS lose exclusivity?

YONDELIS received US orphan-drug designation for relevant indications. Orphan exclusivity generally provides seven years of FDA protection from approval for the designated indication under the Orphan Drug Act.[3] The US approval occurred in October 2015, placing the principal seven-year orphan exclusivity period around October 2022 for the approved indication, subject to the specific designation and regulatory scope.[1][3]

Orphan exclusivity is separate from patent protection. It does not establish a single global expiration date for all YONDELIS rights.

Exclusivity category	YONDELIS position
US approval	October 2015
US orphan exclusivity	Approximately seven years from approval for the protected indication
New chemical entity exclusivity	No current NCE exclusivity expected
Patent protection	Depends on individual patent, extension, and jurisdiction
Regulatory pathway after exclusivity	Potential ANDA or other applicable abbreviated pathway
Biosimilar pathway	Not applicable because trabectedin is a small molecule

The EU regulatory position differs because European marketing authorization and market protection depend on EU pharmaceutical legislation, orphan designation, pediatric obligations, supplementary protection certificates, and country-specific enforcement. A single US date cannot be applied to Europe or other territories.

What is the Orange Book status of YONDELIS?

YONDELIS is an FDA-approved small-molecule drug marketed under NDA 022225.[1] The Orange Book is the relevant US source for listed patents, expiration dates, pediatric exclusivity, and approved therapeutic equivalence codes.[4]

For commercial diligence, the decisive questions are:

• Which patents are currently listed against NDA 022225?
• Which listed patents remain unexpired?
• Are any patents directed to formulation, method of use, or manufacturing?
• Have Paragraph IV certifications been filed?
• Has the reference sponsor initiated litigation within the statutory period?
• Are any settlements limiting generic launch timing?

A patent-by-patent conclusion requires the current Orange Book record and corresponding USPTO and court files. Patent term adjustment, patent term extension, disclaimers, reexamination, terminal disclaimers, and settlement terms can change the effective risk profile.

Are there Paragraph IV challenges to YONDELIS?

A Paragraph IV challenge would require an ANDA applicant to certify that a listed patent is invalid, unenforceable, or will not be infringed. The commercial consequences include potential litigation, a 30-month stay in applicable circumstances, and a possible 180-day first-filer exclusivity period if statutory conditions are met.[5]

For YONDELIS, the key risks are likely to be:

• A formulation challenge based on an alternative excipient system.
• A method-of-use challenge limited to a protected cancer indication.
• A manufacturing-process challenge.
• A patent-term dispute involving listed patents.
• A noninfringement position based on different vial, buffer, or lyophilization conditions.

The absence or presence of a public Paragraph IV case should be confirmed against FDA litigation records and federal court dockets before assigning a launch probability.

Is there biosimilar risk for YONDELIS?

No. Trabectedin is a chemically synthesized small molecule, not a biologic. The relevant competitive threat is a generic injectable or an alternative branded trabectedin product, not a biosimilar under the Public Health Service Act.

A generic applicant would face a different technical package from a biosimilar sponsor. The central issues would be sameness of active ingredient, injectable product quality, sterility, stability, and bioequivalence or FDA-accepted comparative evidence.

How strong is the YONDELIS patent estate?

The estate should be assessed as a layered portfolio rather than by counting patent families alone.

IP layer	Relevance to generic entry
Compound patents	Often strongest early protection, but generally subject to finite term
Manufacturing patents	Can be significant because trabectedin synthesis is complex
Formulation patents	May be designed around through excipient or process changes
Method-of-use patents	Can restrict labeled indication claims after compound expiry
Packaging and device rights	May affect specific presentations but rarely block all injectable entry
Regulatory exclusivity	Can delay approval independently of patent validity

Trabectedin's complex marine-derived chemical structure and manufacturing history can make active-ingredient production more difficult than ordinary generic oncology injectables. A competitor may need specialized process chemistry, impurity control, high-containment handling, and reliable sterile fill-finish capacity.

What manufacturing barriers affect commercial entry?

Trabectedin presents several manufacturing and supply-chain challenges:

• High-potency cytotoxic handling.
• Small-dose accuracy in a 1-mg vial.
• Aseptic lyophilization.
• Control of degradation products.
• Specialized analytical methods.
• Low-volume oncology demand relative to mainstream injectables.
• Hazardous-drug containment.
• Long infusion administration.
• Limited commercial scale economies.

These barriers favor contract development and manufacturing organizations with oncology sterile capacity. Excipient suppliers can capture value by providing validated grades, documentation packages, and technical support rather than commodity materials alone.

Which excipient commercial opportunities are most attractive?

The highest-value opportunities are:

1. Validated sucrose and phosphate systems for sterile lyophilization.
2. Alternative stabilizers that improve residual moisture or reconstitution.
3. Low-extractables vial and stopper systems.
4. Closed-system transfer and reconstitution devices.
5. Ready-to-use or dual-chamber presentations.
6. Compatibility data packages for infusion bags, tubing, and pumps.
7. Contract development services for cytotoxic lyophilized injectables.
8. Analytical methods for related substances, potency, and degradation.
9. Supply-chain services for small-batch sterile oncology products.

The most defensible commercial position is likely to combine excipient supply with formulation development, lyophilization cycle design, container-closure qualification, and regulatory documentation.

How does YONDELIS compare with other oncology injectables?

YONDELIS differs from many conventional oncology injectables because the product is supplied as a lyophilized powder and administered over 24 hours. That creates greater value for reconstitution simplification and infusion compatibility than for oral solubilization technologies.

Attribute	YONDELIS	Conventional liquid oncology injection
Storage form	Lyophilized powder	Ready liquid or concentrate
Main formulation issue	Cake stability and reconstitution	Liquid stability and precipitation
Administration	Prolonged infusion	Often shorter infusion or injection
Excipient opportunity	Stabilizer, buffer, lyophilization, packaging	Solubilizer, surfactant, tonicity agent
Generic barrier	Sterile lyophilization and cytotoxic handling	Liquid stability and container compatibility
Biosimilar pathway	Not applicable	Usually not applicable for small molecules

Key Takeaways

• YONDELIS contains trabectedin in a 1-mg sterile lyophilized vial.
• Its core excipient system includes sucrose, potassium phosphate monobasic, phosphoric acid, and sodium hydroxide.
• Commercial opportunity is concentrated in lyophilization, sterile manufacturing, infusion compatibility, and handling systems.
• A generic applicant may design around the reference formulation, but it must solve stability, sterility, reconstitution, and cytotoxic manufacturing requirements.
• YONDELIS has no biosimilar pathway because trabectedin is a small molecule.
• US orphan exclusivity from the 2015 approval was generally limited to approximately seven years for the protected indication.
• Current Orange Book listings, Paragraph IV activity, and patent settlements determine the remaining US launch risk.
• Ready-to-use and closed-system presentations could create differentiated hospital value if they reduce pharmacy preparation and hazardous-drug handling.

FAQs

What is the main excipient in YONDELIS?

Sucrose is the principal stabilizing and bulking excipient identified in the product formulation. Phosphate components provide buffering, while phosphoric acid and sodium hydroxide support pH adjustment.

Can YONDELIS be reformulated as a liquid injection?

Potentially, but a liquid presentation would require extensive stability, compatibility, container-closure, sterility, and administration-period data. The change would be more complex than substituting one excipient in the existing lyophilized product.

Is trabectedin difficult to manufacture generically?

Yes. The principal challenges include complex active-ingredient production, high-potency cytotoxic handling, low-dose fill accuracy, aseptic lyophilization, impurity control, and specialized analytical testing.

What is the best excipient strategy for a YONDELIS generic?

A sucrose-phosphate lyophilized system is the lowest-risk starting point because it is aligned with the reference product's broad formulation architecture. Differentiated systems may use alternative sugars or buffers, but they require stronger stability and compatibility evidence.

Can a device patent protect a YONDELIS alternative?

A reconstitution device, closed-system transfer system, dual-chamber container, or specialized infusion package may support device or packaging claims. Such rights would not necessarily block all trabectedin products, but they could protect a specific commercial presentation.

References

1. U.S. Food and Drug Administration. (2023). YONDELIS (trabectedin) for injection: Prescribing information. FDA.

2. European Medicines Agency. (2024). Yondelis: EPAR product information. EMA.

3. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions and Paragraph IV certifications. FDA.

6. PharmaMar, S.A. (2024). Annual report and financial information. PharmaMar.